MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
about
Rett Syndrome: Crossing the Threshold to Clinical TranslationBDNF deregulation in Rett syndromeTargeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesIllness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1).Rett Syndrome: Reaching for Clinical TrialsRole of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy.Female Mecp2(+/-) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies.Beyond Widespread Mecp2 Deletions to Model Rett Syndrome: Conditional Spatio-Temporal Knockout, Single-Point Mutations and Transgenic Rescue MicePreclinical research in Rett syndrome: setting the foundation for translational success.MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways.Gene × Environment interactions in autism spectrum disorders: role of epigenetic mechanisms.Neuronal SUMOylation: mechanisms, physiology, and roles in neuronal dysfunction.Knock-down of methyl CpG-binding protein 2 (MeCP2) causes alterations in cell proliferation and nuclear lamins expression in mammalian cells.Remote regulation of glucose homeostasis in mice using genetically encoded nanoparticlesGait analysis in a Mecp2 knockout mouse model of Rett syndrome reveals early-onset and progressive motor deficitsBiomechanical properties of bone in a mouse model of Rett syndrome.Beta-actin deficiency with oxidative posttranslational modifications in Rett syndrome erythrocytes: insights into an altered cytoskeletal organizationPancreatic B-13 Cell Trans-Differentiation to Hepatocytes Is Dependent on Epigenetic-Regulated Changes in Gene ExpressionSynaptic plasticity in mouse models of autism spectrum disorders.Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice.Correcting deregulated Fxyd1 expression ameliorates a behavioral impairment in a mouse model of Rett syndrome.Peripheral administration of brain-derived neurotrophic factor to Rett syndrome animal model: a possible approach for the treatment of Rett syndromeTraining communication abilities in Rett Syndrome through reading and writing.Transcriptional regulation in pluripotent stem cells by methyl CpG-binding protein 2 (MeCP2).Neurobiologically-based treatments in Rett syndrome: opportunities and challenges.The role of oxidative stress in Rett syndrome: an overview.Making headway with genetic diagnostics of intellectual disabilities.Genetics, molecular biology, and phenotypes of x-linked epilepsy.Recent genetic findings in schizophrenia and their therapeutic relevance5-hydroxymethylcytosine: a potential therapeutic target in cancer.MeCP2, a target of miR-638, facilitates gastric cancer cell proliferation through activation of the MEK1/2-ERK1/2 signaling pathway by upregulating GIT1.An RNA interference screen identifies druggable regulators of MeCP2 stability.Respiratory disturbances in rett syndrome: don't forget to evaluate upper airway obstruction.Developmental abnormalities of cortical interneurons precede symptoms onset in a mouse model of Rett syndrome.Gene therapy for Rett syndrome: prospects and challenges
P2860
Q26772909-CCE4BEA1-A9B2-4C9F-9381-1FB4C3708915Q27005901-D7B54A56-332C-4080-9EA7-2F59AA4BA19BQ27023257-35B129B3-93A9-47D2-B6BC-180F8DA59591Q27312920-F2A13330-29AC-4D5D-BDB3-CDBBB0A2560CQ27337778-F221D182-E609-421D-AE67-B7313F0B8137Q30235312-C32B26D6-834A-438D-9F11-15DA91502286Q30445073-1EF5C70B-8841-40A2-96BF-6A0A4AD0CA5AQ30450914-A05D5111-A1DA-4896-8E7B-54EDEBD2BAC1Q30527828-9599F191-AE4D-4B33-A62A-399F33F6148CQ33809732-0DC9BAE2-C644-406E-9B40-F1B4B8D26EE9Q33997473-319ADD1A-04DD-488A-9E06-6FA60C8A2AB0Q34295237-4DD88992-C503-4A00-9E9F-E723F571A4ADQ34333224-D3D4CC3E-5720-40F8-88B2-4CE22DD9C2C2Q34453524-BDD5E7BE-A754-41E0-A381-41A16B7454A6Q34506454-56FD8D95-D7C5-431D-B06C-EDD771B7B538Q34906346-6266FBE4-98F1-4EFD-9647-35FCF32265D8Q35132215-E29E705C-41F7-4B3F-8803-63EE1A29F8E4Q35949116-6F526446-365B-4F5B-BAE0-074759F7B5EFQ36479094-D86EE000-B91E-402D-8748-32FE47FB73C6Q36507871-344714F0-BAB1-4153-9C37-3777CA3FEE54Q36565518-548F46AB-2038-4A1C-8F06-FE8B84A4B9D5Q36577222-BC1FA6D0-EDE2-4F57-9541-4A0F0539FDA1Q37371802-AA85009C-AAD4-48CF-B083-608B84DED80AQ37508598-4818556F-419B-4634-A7D7-13AF36699B37Q37558440-4531D153-220A-459B-BB6B-56A0421E2D6CQ38023570-F2A8565C-63B0-4F4A-BDEA-E40414358BE6Q38124929-91814739-5D8E-44DA-8F7C-3BB4F84A3139Q38164570-4FD9E2DF-CFF1-492B-98B0-4394F9051C94Q38260258-2560D9B9-7836-4C18-B5DF-466E8A40B1CCQ38272312-9ABE79CF-4E66-49C3-BC12-07ACED0B05AEQ41228798-E85F9BA5-2842-4497-B0CB-9C1D153D7CDCQ46022392-10C86459-ABD3-4FB5-96E8-C5087ACD7782Q48261341-D1DEF5D1-3CBC-464C-9372-B9D9D7CD3FCDQ48686214-0406CAF6-A524-4F28-B275-F4778511AA2EQ57677438-B10F9C0F-A5B9-467D-B1EC-4DB0778CB14C
P2860
MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
@en
MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
@nl
type
label
MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
@en
MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
@nl
prefLabel
MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
@en
MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
@nl
P2860
P356
P1433
P1476
MeCP2 and Rett syndrome: reversibility and potential avenues for therapy
@en
P2093
Kamal K E Gadalla
Stuart R Cobb
P2860
P356
10.1042/BJ20110648
P407
P577
2011-10-01T00:00:00Z